Tamara Haque

Dr. Tamara Haque

National Institutes of Health, Bethesda, Maryland, USA
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2024 in Science Immunology
Verified
Journal Article
Closed access
THTamara Haque
Tamara Haque
KWKatherine A. Weissler
Katherine A. Weissler
ZSZoe Schmiechen
Zoe Schmiechen
KLKaren Laky
Karen Laky
DSDaniella M. Schwartz
Daniella M. Schwartz
PFPamela A. Frischmeyer-Guerrerio
Pamela A. Frischmeyer-Guerrerio
Allergic diseases are common, affecting more than 20% of the population. Genetic variants in the TGFβ pathway are strongly associated with atopy. To interrogate the mechanisms underlying this association, we examined patients and mice with Loeys-Dietz syndrome (LDS) who harbor missense mutations in the kinase domain of TGFΒR1/2 . We demonstrate that LDS mutations lead to reduced TGFβ signaling and elevated total and allergen-specific IgE, despite the presence of wild-type T regulatory cells in a chimera model. Germinal center activity was enhanced in LDS and characterized by a selective increase in type 2 follicular helper T cells (T FH 2). Expression of Pik3cg was increased in LDS T FH cells and associated with reduced levels of the transcriptional repressor SnoN. PI3Kγ/mTOR signaling in LDS naïve CD4 + T cells was elevated after T cell receptor cross-linking, and pharmacologic inhibition of PI3Kγ or mTOR prevented exaggerated T FH 2 and antigen-specific IgE responses after oral antigen exposure in an adoptive transfer model. Naïve CD4 + T cells from nonsyndromic allergic individuals also displayed decreased TGFβ signaling, suggesting that our mechanistic discoveries may be broadly relevant to allergic patients in general. Thus, TGFβ plays a conserved, T cell–intrinsic, and nonredundant role in restraining T FH 2 development via the PI3Kγ/mTOR pathway and thereby protects against allergic disease.

Verified
Journal Article
Open access
PDF file
THTamara Haque
Tamara Haque
PFPamela A Frischmeyer-Guerrerio
Pamela A Frischmeyer-Guerrerio
Mast cells (MC) are a key effector cell in multiple types of immune responses, including atopic conditions. Allergic diseases have been steadily rising across the globe, creating a growing public health problem. IgE-mediated activation of MCs leads to the release of potent mediators that can have dire clinical consequences. Current therapeutic options to inhibit MC activation and degranulation are limited; thus, a better understanding of the mechanisms that regulate MC effector functions in allergic inflammation are necessary in order to develop effective treatment options with minimal side effects. Several cytokines have been identified that play multifaceted roles in regulating MC activation, including TGFβ, IL-10, and IL-33, and others that appear to serve primarily anti-inflammatory functions, including IL-35 and IL-37. Here, we review the literature examining cytokines that regulate MC-mediated allergic immune responses.

20 May 2020 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
PPPatrick A. Paez
Patrick A. Paez
EKElizabeth Motunrayo Kolawole
Elizabeth Motunrayo Kolawole
MTMarcela T. Taruselli
Marcela T. Taruselli
SASiddarth Ajith
Siddarth Ajith
JDJordan M. Dailey
Jordan M. Dailey
JRJohn Joseph Ryan
John Joseph Ryan
Statin drugs are widely employed in the clinic to reduce serum cholesterol. Because of their hydroxymethylglutaryl coenzyme A reductase antagonism, statins also reduce isoprenyl lipids necessary for the membrane anchorage and signaling of small G-proteins in the Ras superfamily. We previously found that statins suppress immunoglobulin E (IgE)-mediated mast cell activation, suggesting these drugs might be useful in treating allergic disease. Although IgE-induced function is critical to allergic inflammation, mast cell proliferation and survival also impact atopic disease and mast cell neoplasia. In this study, we describe fluvastatin-mediated apoptosis in primary and transformed mast cells. An IC50 was achieved between 0.8 and 3.5 μM in both cell types, concentrations similar to the reported fluvastatin serum Cmax value. Apoptosis was correlated with reduced stem cell factor (SCF)-mediated signal transduction, mitochondrial dysfunction, and caspase activation. Complementing these data, we found that p53 deficiency or Bcl-2 overexpression reduced fluvastatin-induced apoptosis. We also noted evidence of cytoprotective autophagy in primary mast cells treated with fluvastatin. Finally, we found that intraperitoneal fluvastatin treatment reduced peritoneal mast cell numbers in vivo. These findings offer insight into the mechanisms of mast cell survival and support the possible utility of statins in mast cell–associated allergic and neoplastic diseases. SIGNIFICANCE STATEMENT Fluvastatin, a statin drug used to lower cholesterol, induces apoptosis in primary and transformed mast cells by antagonizing protein isoprenylation, effectively inhibiting stem cell factor (SCF)-induced survival signals. This drug may be an effective means of suppressing mast cell survival.

1 June 2021 in Cellular Immunology
Verified
Journal Article
Closed access
KKKasalina N. Kiwanuka
Kasalina N. Kiwanuka
EKElizabeth Motunrayo Kolawole
Elizabeth Motunrayo Kolawole
JMJamie Josephine Avila Mcleod
Jamie Josephine Avila Mcleod
BBBianca Baker
Bianca Baker
PPPatrick A. Paez
Patrick A. Paez
JRJohn Joseph Ryan
John Joseph Ryan

12 September 2023 in Science Signaling
Verified
Journal Article
Closed access
THTamara Haque
Tamara Haque
MTMarcela T. Taruselli
Marcela T. Taruselli
SKSydney A. Kee
Sydney A. Kee
JDJordan M. Dailey
Jordan M. Dailey
NPNeha Pondicherry
Neha Pondicherry
JRJohn Joseph Ryan
John Joseph Ryan
There is a clinical need for new treatment options addressing allergic disease. Selective serotonin reuptake inhibitors (SSRIs) are a class of antidepressants that have anti-inflammatory properties. We tested the effects of the SSRI fluoxetine on IgE-induced function of mast cells, which are critical effectors of allergic inflammation. We showed that fluoxetine treatment of murine or human mast cells reduced IgE-mediated degranulation, cytokine production, and inflammatory lipid secretion, as well as signaling mediated by the mast cell activator ATP. In a mouse model of systemic anaphylaxis, fluoxetine reduced hypothermia and cytokine production. Fluoxetine was also effective in a model of allergic airway inflammation, where it reduced bronchial responsiveness and inflammation. These data show that fluoxetine suppresses mast cell activation by impeding an FcɛRI-ATP positive feedback loop and support the potential repurposing of this SSRI for use in allergic disease.

18 July 2023 in Frontiers in Allergy
Verified
Journal Article
Open access
SKStephanie Kubala
Stephanie Kubala
THTamara Haque
Tamara Haque
Editorial: Mast cells in allergic diseases